Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Tripterygium Wilfordii in Patients With Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years with informed consent~* Diagnosed with rheumatoid arthritis as determined by meeting the 2010 ACR/EULAR classification criteria and has had rheumatoid arthritis for at least 6 weeks~* Swollen joint (SJC)≥3 and tender joint count(TJC)≥5~* ESR \>28 mm/hr or C-reactive protein \> 20 mg/L~Exclusion Criteria:~* Pregnant, lactating or further fertility requirements~* Previous treated with methotrexate or biologic DMARD.~* Active or chronic infection, including HIV, HCV, HBV, tuberculosis~* Patient with cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Methotrexate (Type: PLACEBO_COMPARATOR): Patients were treated with methotrexate alone.
- T2 (Type: EXPERIMENTAL): Patients were treated with oral T2 (chloroform/methanol extract of Tripterygium wilfordii Hook F).
- MTX+T2 (Type: EXPERIMENTAL): The patients were treated with methotrexate and T2.

Based on this trial design, predict the completion outcome and termination type (if applicable).